Weekly Highlights: Executive Changes at Three Pharma Firms and Latest Hospital Payment Reforms
Sinopharm
Pharmaceutical and Medical Device Distributors and Supply Chain Service Providers
Fosun Pharmaceutical
Healthcare Industry Group
Qilu Pharmaceutical
Specialty Formulations and Active Pharmaceutical Ingredients (API) Developer
Zhongxin Pharmaceutical
TCM Research and Development, Manufacturer
"Weekly Highlights"
"Weekly Highlights" is a column launched by Siqi Club to summarize the major events in the pharmaceutical industry on a weekly basis, covering the latest policy trends, news updates, pharmaceutical finance, and progress in drug approvals.
Personnel Changes
HUMAN RESOURCES
Chairman of Sinopharm Group Co., Ltd. Replaced
Recently, Sinopharm Group Co., Ltd. announced changes in the composition of its board committees, with Zhao Bingxiang appointed as a non-executive director of Sinopharm.
According to the process outlined in the "State-controlled Board Resolution" at the end of August, Zhao Bingxiang was elected as the Chairman of the Board. This appointment will only take effect after the shareholders approve his appointment as a non-executive director at the shareholders' meeting. Zhao Bingxiang's appointment as a non-executive director of Sinopharm Group Co., Ltd. also signifies the effectiveness of his role as Chairman.
Eli Lilly China Vice President Resigns
According to "Luo Shi Xiong" news, Fu Qi Yue, Vice President of Lilly China's Biomedicines Division, is about to leave her position, with her last working day on September 30, 2024.
Fosun Pharmaceutical Executive President Resigns
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. announced that, effective from September 13, Mr. Li Shengli will no longer serve as the Executive President of the Company.
Policy Brief
POLICY
Hospital Repayment, Latest Adjustment
On September 13, the Jiangxi Provincial Medical Insurance Bureau released the "Notice on the Direct Settlement of Payments for National Medical Insurance Negotiated Drugs by the Medical Insurance Fund and Pharmaceutical Suppliers (Draft for Soliciting Opinions)." Jiangxi Province will implement direct settlement of payments by the medical insurance fund for the procurement and use of national medical insurance negotiated drugs within the agreement period by designated medical institutions under the medical insurance scheme, establishing a direct settlement revolving fund for nationally negotiated drugs.
Pharmaceutical News Updates
PHARMA
Qilu Pharmaceutical's Semaglutide Injection Submitted for Market Approval
On September 15, the website of the Center for Drug Evaluation (CDE) under the China National Medical Products Administration (NMPA) announced that the marketing application for the semaglutide injection submitted by Qilu Pharmaceutical has been accepted. The specific indications have not yet been disclosed.
AbbVie's "Venetoclax Tablets" New Indication Submitted for Marketing Approval in China
On September 20, the official website of the Center for Drug Evaluation (CDE) under the China National Medical Products Administration (NMPA) announced that AbbVie's new indication application for Venetoclax Tablets has been accepted, but the specific indication has not yet been disclosed.
Gannex Pharma Enters the Obesity Drug Market
On September 17, Ascletis Pharma announced that its small molecule GLP-1R agonist ASC30 is undergoing two Phase I clinical trials in the United States for once-monthly subcutaneous injection and once-daily oral tablet formulations for the treatment of obesity.
Pharmaceutical Finance
BUSINESS
Zhongxin Pharmaceutical Divests Pharmaceutical Commercial Sector
Zhongxin Pharmaceutical announced that it plans to transfer all the equity of its wholly-owned subsidiary, Tianjin Zhongxin Pharmaceutical Co., Ltd., to Jiuyao Taiping Pharmaceutical Co., Ltd., a wholly-owned subsidiary of its controlling shareholder, Tianjin Pharmaceutical Group Co., Ltd., in the form of capital increase. The transaction amount is approximately 4.94 billion yuan.
Ant Group Invests in Haodaifu Online
Southern Finance and Economics News, September 14: According to the Tianyancha App, Hu Dong Feng Technology (Beijing) Co., Ltd., a company associated with Haodf Online, recently underwent industrial and commercial changes. Original shareholders Wang Hang, Hu Shaoyu, Lei Jun, and others exited, while Shanghai Yun Chang Enterprise Management Consulting Co., Ltd., a subsidiary of Ant Group, became the new sole shareholder. At the same time, the legal representative also changed.
Organon to Acquire Dermavant from Roivant
Organon has agreed to acquire Dermavant, a subsidiary of Roivant, for up to $1.2 billion, thereby expanding its influence in the dermatology treatment market.
Business Cooperation
130 6172 3098
zakk.cui@siqibest.com
ClickRead the original text Learn More